Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADAP Adaptimmune Therapeutics	$0.28 +1.1%	$0.27	$0.20 ▼ $1.48	$73.29M	2.18	1.60 million shs	608,058 shs
AGEN Agenus	$6.15 -8.5%	$4.73	$1.38 ▼ $7.34	$184.24M	1.51	706,643 shs	1.08 million shs
AUTL Autolus Therapeutics	$2.41 -0.4%	$2.04	$1.11 ▼ $5.00	$644.06M	1.81	1.57 million shs	1.50 million shs
OYST Oyster Point Pharma	$11.17	$11.15	$3.46 ▼ $19.00	$299.85M	1.31	212,171 shs	330 shs
TBIO Telesis Bio	$0.02	$0.11	$0.01 ▼ $6.17	$44K	2.89	6,682 shs	9 shs

Investing Strategies To Help Grow Your Retirement Income

Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADAP Adaptimmune Therapeutics	+2.41%	+0.80%	+7.88%	+16.08%	-78.06%
AGEN Agenus	+5.66%	+13.51%	+40.59%	+223.08%	-62.10%
AUTL Autolus Therapeutics	-0.82%	-2.42%	+19.21%	+69.23%	-45.37%
OYST Oyster Point Pharma	0.00%	0.00%	0.00%	0.00%	0.00%
TBIO Telesis Bio	0.00%	-91.90%	-51.40%	-97.36%	-99.38%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ADAP Adaptimmune Therapeutics	1.8158 of 5 stars	3.1	4.0	0.0	0.0	1.6	0.8	0.0
AGEN Agenus	4.2638 of 5 stars	3.2	4.0	0.0	4.6	2.1	1.7	0.6
AUTL Autolus Therapeutics	2.6855 of 5 stars	3.5	1.0	0.0	0.0	2.6	3.3	0.6
OYST Oyster Point Pharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
TBIO Telesis Bio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADAP Adaptimmune Therapeutics	2.29	Hold	$1.35	383.60% Upside
AGEN Agenus	2.40	Hold	$14.00	127.64% Upside
AUTL Autolus Therapeutics	3.00	Buy	$9.32	286.72% Upside
OYST Oyster Point Pharma	0.00	N/A	N/A	N/A
TBIO Telesis Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest TBIO, AUTL, OYST, AGEN, and ADAP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	ADAP Adaptimmune Therapeutics	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$1.50 ➝ $0.50
6/12/2025	AUTL Autolus Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/4/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$4.00 ➝ $6.00
6/4/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$25.00
5/14/2025	ADAP Adaptimmune Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$1.50 ➝ $1.00
5/14/2025	ADAP Adaptimmune Therapeutics	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Underweight ➝ Underweight	$1.00 ➝ $0.46
5/13/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
5/13/2025	AGEN Agenus	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$3.00 ➝ $4.00
4/30/2025	AGEN Agenus	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral
4/21/2025	AGEN Agenus	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADAP Adaptimmune Therapeutics	$178.03M	0.42	N/A	N/A	$0.05 per share	5.59
AGEN Agenus	$103.46M	1.63	N/A	N/A	($13.06) per share	-0.47
AUTL Autolus Therapeutics	$10.12M	63.38	N/A	N/A	$1.61 per share	1.50
OYST Oyster Point Pharma	$24.54M	12.22	N/A	N/A	$3.80 per share	2.94
TBIO Telesis Bio	$225.09M	0.00	N/A	N/A	$0.14 per share	0.17

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADAP Adaptimmune Therapeutics	-$70.81M	-$0.27	0.00	N/A	N/A	-38.91%	-163.73%	-23.65%	8/11/2025 (Estimated)
AGEN Agenus	-$227.21M	-$8.67	0.00	N/A	N/A	-196.12%	N/A	-82.33%	8/6/2025 (Estimated)
AUTL Autolus Therapeutics	-$220.66M	-$0.88	0.00	N/A	N/A	N/A	-52.82%	-29.67%	8/14/2025 (Estimated)
OYST Oyster Point Pharma	-$100.66M	-$6.65	N/A	N/A	N/A	-901.99%	-490.33%	-108.29%	N/A
TBIO Telesis Bio	-$47.72M	-$28.20	N/A	∞	N/A	-336.59%	N/A	-61.89%	8/5/2025 (Estimated)

Latest TBIO, AUTL, OYST, AGEN, and ADAP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	AGEN Agenus	-$0.78	N/A	N/A	N/A	$49.71 million	N/A
8/14/2025	Q2 2025	AUTL Autolus Therapeutics	-$0.2329	N/A	N/A	N/A	$12.92 million	N/A
8/11/2025	Q2 2025	ADAP Adaptimmune Therapeutics	-$0.11	N/A	N/A	N/A	$11.04 million	N/A
5/13/2025	Q1 2025	ADAP Adaptimmune Therapeutics	-$0.18	-$0.18	N/A	-$0.18	$6.55 million	$7.29 million
5/12/2025	Q1 2025	AGEN Agenus	-$1.61	-$1.03	+$0.58	-$1.03	$26.38 million	$24.07 million
5/8/2025	Q1 2025	AUTL Autolus Therapeutics	-$0.24	-$0.26	-$0.02	-$0.26	$1.59 million	$8.98 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADAP Adaptimmune Therapeutics	N/A	N/A	N/A	N/A	N/A
AGEN Agenus	N/A	N/A	N/A	N/A	N/A
AUTL Autolus Therapeutics	N/A	N/A	N/A	N/A	N/A
OYST Oyster Point Pharma	N/A	N/A	N/A	N/A	N/A
TBIO Telesis Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADAP Adaptimmune Therapeutics	4.24	2.02	1.79
AGEN Agenus	N/A	0.11	0.11
AUTL Autolus Therapeutics	N/A	9.24	9.02
OYST Oyster Point Pharma	8.49	3.35	3.11
TBIO Telesis Bio	N/A	1.23	1.06

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADAP Adaptimmune Therapeutics	31.37%
AGEN Agenus	61.46%
AUTL Autolus Therapeutics	72.83%
OYST Oyster Point Pharma	96.70%
TBIO Telesis Bio	37.63%

Insider Ownership

Company	Insider Ownership
ADAP Adaptimmune Therapeutics	12.74%
AGEN Agenus	5.50%
AUTL Autolus Therapeutics	25.70%
OYST Oyster Point Pharma	17.90%
TBIO Telesis Bio	24.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADAP Adaptimmune Therapeutics	490	265.05 million	231.28 million	Optionable
AGEN Agenus	440	27.42 million	25.91 million	Optionable
AUTL Autolus Therapeutics	330	266.14 million	197.74 million	Optionable
OYST Oyster Point Pharma	303	26.84 million	22.04 million	Not Optionable
TBIO Telesis Bio	200	1.80 million	1.36 million	Optionable

TBIO, AUTL, OYST, AGEN, and ADAP Headlines

Recent News About These Companies

Telesis Bio Inc (TBIO) Stock Forums - Investing.com

June 29, 2025 | investing.com

Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

May 28, 2025 | finance.yahoo.com

Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

March 20, 2025 | finance.yahoo.com

Telesis Bio: Q3 Earnings Snapshot

November 8, 2024 | timesunion.comT

Telesis Bio Announces Departure of Chief Legal Officer

October 25, 2024 | markets.businessinsider.com

Telesis Bio Shares Double After News of Beckman Coulter Life Sciences Collaboration

September 27, 2024 | marketwatch.com

What's Going On With Telesis Bio Shares Thursday?

September 27, 2024 | msn.com

Telesis Bio Inc (TBIO) Stock: More Strategic Than Meets the Eye

September 27, 2024 | bovnews.comB

Telesis Bio Stock Is Soaring Wednesday: What's Going On?

September 26, 2024 | msn.com

Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

September 25, 2024 | globenewswire.com

The TBIO Conundrum: Why Telesis Bio Inc’s Stock Is Making Headlines Again

September 21, 2024 | bovnews.comB

Telesis Bio Inc (TBIO) Stock: Greater Than Its Current Valuation?

September 19, 2024 | bovnews.comB

Telesis Bio Plans to Delist its Securities from The Nasdaq Stock Market

September 10, 2024 | globenewswire.com

Telesis Bio Names CEO Eric Esser as Chair After Five Board Members Resign

August 30, 2024 | marketwatch.com

Telesis Bio Inc

August 15, 2024 | money.usnews.com

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q2 2024

August 7, 2024 | msn.com

Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

August 7, 2024 | finance.yahoo.com

Telesis Bio (NASDAQ:TBIO) Stock, Short Interest Report

July 31, 2024 | benzinga.com

TBIO Stock Earnings: Telesis Bio Misses EPS, Misses Revenue for Q1 2024

May 10, 2024 | investorplace.com

Telesis Bio Reports First Quarter 2024 Financial Results

May 9, 2024 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
3 Defense Leaders Set to Gain From Rising Military Spend
By Chris Markoch | July 5, 2025
View 3 Defense Leaders Set to Gain From Rising Military Spend
IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
By Dan Schmidt | June 20, 2025
View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s Surge
BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
By Gabriel Osorio-Mazilli | June 23, 2025
View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense
SoundHound Rises as Short Sellers Exit and AI Demand Grows
By Thomas Hughes | July 9, 2025
View SoundHound Rises as Short Sellers Exit and AI Demand Grows

TBIO, AUTL, OYST, AGEN, and ADAP Company Descriptions

Adaptimmune Therapeutics NASDAQ:ADAP

$0.28 +0.00 (+1.08%)

Closing price 04:00 PM Eastern

Extended Trading

$0.27 -0.01 (-3.76%)

As of 06:55 PM Eastern

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

Agenus NASDAQ:AGEN

$6.15 -0.57 (-8.48%)

Closing price 04:00 PM Eastern

Extended Trading

$6.22 +0.06 (+1.06%)

As of 07:46 PM Eastern

Agenus Inc., a clinical-stage biotechnology company, discovers and develops immuno-oncology products in the United States and internationally. The company offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies. It develops QS-21 Stimulon adjuvant, a saponin-based vaccine adjuvant. The company also develops Balstilimab, an anti-PD-1 antagonist that has completed Phase II clinical trial to treat second line cervical cancer; AGEN1181, an antigen 4 (CTLA-4) blocking antibody that is in Phase 2 clinical trial for the treatment of pancreatic cancer and and melanoma; AGEN2373, a CD137 monospecific antibody that is in Phase 1b clinical trial; AGEN1423, a CD73/TGFß TRAP antibody; AGEN1571, an ILT2 monospecific antibody that is in Phase 1 clinical trial; and BMS-986442, a TIGIT bispecific antibodies. In addition, it develops INCAGN1876, a GITR agonist; INCAGN2390, a TIM-3 monospecific antibody; INCAGN2385, a LAG-3 monospecific antibody; MK-4830, a monospecific antibody targeting ILT4 that is in Phase 2 clinical trial; UGN-301, a zalifrelimab intravesical solution for the treatment of cancers of the urinary tract that is in a Phase 1 clinical trial; and AGEN1884, a first-generation anti-CTLA-4 monospecific antibody. The company operates under Agenus, MiNK, Prophage, Retrocyte Display, and Stimulon trademarks. It has collaborations with Bristol-Myers Squibb Company, Betta Pharmaceuticals Co., Ltd., Incyte Corporation, Merck Sharpe & Dohme, and Gilead Sciences, Inc. The company was formerly known as Antigenics Inc. and changed its name to Agenus Inc. in January 2011. Agenus Inc. was founded in 1994 and is headquartered in Lexington, Massachusetts.

Autolus Therapeutics NASDAQ:AUTL

$2.41 -0.01 (-0.41%)

Closing price 04:00 PM Eastern

Extended Trading

$2.40 -0.01 (-0.21%)

As of 06:41 PM Eastern

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma. It focuses on developing AUTO5, a preclinical TRBC2 programmed T cell product candidate for the treatment of peripheral T-cell lymphoma. Autolus Therapeutics plc was incorporated in 2014 and is headquartered in London, the United Kingdom.

Oyster Point Pharma NASDAQ:OYST

Oyster Point Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ophthalmic diseases in the United States. The company's product candidate is TYRVAYA, a nicotinic acetylcholine receptor agonist for the treatment of signs and symptoms of dry eye disease. It is also developing TYRVAYA that is in Phase II clinical trial for the treatment of for neurotrophic keratopathy. The company was incorporated in 2015 and is headquartered in Princeton, New Jersey.

Telesis Bio NASDAQ:TBIO

$0.02 0.00 (0.00%)

As of 07/17/2025

Telesis Bio, Inc., a synthetic biology company, manufactures and sells synthetic biology instruments, reagents, and associated products and related services, primarily to pharmaceutical and academic laboratories worldwide. The company offers BioXp 3250 system and BioXp 9600 system that empower researchers to go from a digital DNA sequence to endpoint-ready synthetic deoxyribonucleic acid (DNA) and messenger ribonucleic acid (mRNA) with onboard next generation sequencing (NGS) library preparation; BioXp portal, an online portal that offers an intuitive guided workflow and design tools for building new DNA sequences and assembling them into vectors of choice, as well as mRNA constructs; and BioXp De Novo kits, which contains building blocks and reagents, including proprietary Gibson assembly branded reagents for specific synthetic biology workflow applications. It also provides BioXp Select kits that offers to use non-telesis bio DNA while using the BioXp system to perform synthetic biology workflow applications, such as cloning, mRNA generation from plasmid, and cell free amplification; BioXp Next Generation Sequencing kits, which contains reagents to go from DNA or RNA to a sequencer-ready library; Benchtop reagents that contains the reagents to proceed specific synthetic biology workflow on the benchtop using products generated on the BioXp system; and custom Gibson short oligo ligation assembly enzymatic DNA synthesis solutions, which is designed to construct synthetic DNA, RNA, and proteins for development of mRNA-based vaccines, diagnostics, therapeutics, and personalized medicines. The company serves its products to government institutions, contract research organizations, and synthetic biology companies. The company was formerly known as Codex DNA, Inc. and changed its name to Telesis Bio Inc. in November 2022. Telesis Bio, Inc. was incorporated in 2011 and is headquartered in San Diego, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time